Fate Therapeutics stock: New hires receive 300,000 options

Published on 11/05/2026 at 03:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fate Therapeutics stock follows a new employee award package announced on November 3. The grants carry four-year vesting schedules.

Key points for investors

Fate Therapeutics granted stock options and restricted stock units to newly hired employees on November 2.
The awards are designed to vest over four years and require continued employment.
The company is advancing cell-based therapies for cancer and immune disorders.

FATE, US31189P1021, Illustration mit AI erstellt.

Fate Therapeutics announced on November 3 that it had granted equity awards to newly hired employees. The company disclosed the awards in a GlobeNewswire release.

Equity awards target new hires

On November 2, Fate Therapeutics granted non-qualified options to one newly hired non-executive employee covering 300,000 common shares. The options carry an exercise price of 2.01 US dollars per share, matching the Nasdaq closing price on the grant date.

The company also granted restricted stock units representing 87,000 shares to two newly hired non-executive employees, including the option recipient. The compensation committee approved both awards under the company's amended and restated inducement equity plan and Nasdaq Listing Rule 5635(c)(4).

Four-year vesting sets retention period

The options vest 25 percent after the first year, with the remaining portion vesting in roughly equal monthly installments over the following 36 months. The restricted stock units vest in equal annual portions over four years, subject to continued employment.

The real-time quote of Fate Therapeutics stock was 1.87 euros on Lang & Schwarz at 23:00 CET on Wednesday, November 4, 2026.

Business centers on cell therapies

Fate Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego, United States. It develops programmed cellular immunotherapies for cancer and immune disorders, using an ex vivo cell-programming approach to control the function and fate of hematopoietic cells. Its pipeline includes cell-based therapies derived from induced pluripotent stem cells as well as T-cell and natural-killer-cell candidates.